The treatment of stage I non-small-cell lung cancer has advanced markedly over the past century. The transition from therapeutic nihilism with ensured mortality to radical surgery with pneumonectomy to rational oncologic-based resection has resulted in dramatically improved outcomes and reduced morbidity. The superiority of anatomic resection with lobectomy over sublobar resection for fit patients with stage I disease, where more than one half of all patients should expect to be cured, is backed by level 1 evidence. Minimally invasive approaches have further decreased morbidity and mortality, and prospective trials continue to assess whether sublobar resection is appropriate in more select circumstances for tumors , 2 cm. Interest in studying the patient at high risk for complications after lobectomy has been spurred by recent advances in surgical, radiotherapy, and ablative treatment options. In particular, provocative results with stereotactic body radiotherapy have led to rapid adoption in clinical practice with a resultant decrease in the number of untreated patients. A comparison of outcomes across studies of competing modalities remains challenging given the potential impact of selection bias in single-arm trials, and attempts to conduct randomized studies have been largely unsuccessful. Given the uncertainty in defining optimal therapy, patients are best served by a multidisciplinary team of thoracic surgeons, radiation oncologists, pulmonologists, and chest and interventional radiologists to ensure that they receive the evaluation and treatment best suited not only to their tumor and medical challenges but also to their concerns, fears, and values.
INTRODUCTION
Despite the substantial decline in cigarette smoking in the United States during the past several decades, lung cancer remains the most common cause of cancer deaths in both men and women. The American Cancer Society reported 224,390 new cases and 158,080 deaths as a result of lung cancer in 2016. 1 Approximately 15% of patients with non-small-cell lung cancer (NSCLC) present with localized diseased confined to the primary tumor site. Stage I NSCLC is subdivided into stage IA, which includes patients with primary T1a (, 2 cm) or T1b (2 to 3 cm) tumors, whereas stage IB includes T2a tumors (3 to 5 cm). 2 Given the direct relationship between prognosis and tumor size, the next version of the International Association for the Study of Lung Cancer staging system includes subclassification of T1 into T1a (# 1 cm), T1b (. 1 to # 2 cm), and T1c (. 2 to # 3 cm) and T2 into T2a (. 3 to # 4 cm) and T2b (. 4 to # 5 cm). 3 
Treatment Considerations for Fit Patients
Standard therapy for patients with stage I lung cancer is anatomic surgical resection with lobectomy and sampling of regional lymph nodes. The Lung Cancer Study Group initiated a phase III randomized trial in the 1980s that compared lobectomy with sublobar resection for pathologic stage I NSCLC. 4 Sublobar resection consisted of either segmentectomy, which included an anatomic bronchovascular dissection, or wedge resection, which did not follow anatomic boundaries. Sublobar resection was associated with a significantly increased risk of local relapse compared with lobectomy, and the highest risk of local relapse was after wedge resection. Although lung cancerrelated survival was worse in the sublobar resection group, the difference in overall survival was not statistically significant. More recent randomized trials in the United States and Japan continue to reevaluate the role of sublobar resection when lesions are restricted to # 2 cm. 5, 6 The use of minimally invasive surgery to reduce morbidity compared with open thoracotomy is supported by a review of 39 studies in 6,000 patients with early-stage NSCLC, which showed shorter chest tube duration, shorter length of hospital stay, and improved 4-year survival for thoracoscopic resection compared with thoracotomy. 7 Surgical morbidity was likewise reduced with thoracoscopic lobectomy in a propensitymatched analysis of the Society of Thoracic Surgeons database, which suggests preference of thoracoscopic lobectomy for appropriate patients. 8 The offer of sublobar resection to select fit patients generally is based on the presumption of improved perioperative morbidity and mortality compared with lobectomy. A retrospective series suggested that for peripheral stage I lung cancers, perioperative morbidity is reduced with wedge resection and further reduced by thoracoscopic wedge resection compared with open lobectomy. 9 In the Lung Cancer Study
Group trial, decreases in pulmonary function were significantly worse in the lobectomy group, 4 but this finding did not translate to higher perioperative morbidity. This question of relative postoperative morbidity may be settled with data from the aforementioned randomized prospective trials. 5, 6 Segmentectomy allows access to more centralized tumors and permits resection with greater margins than wedge resection. Given the anatomic nature of resection, segmentectomy has been postulated to be equivalent to lobectomy in select retrospective series. However, results from a large SEER analysis showed reduced overall survival with segmentectomy compared with lobectomy, which suggests that segmentectomy should be used with caution in fit patients with earlystage disease. 10 One situation where sublobar resection is favored over lobectomy even in fit patients is the treatment of ground glass opacities that require surgical intervention. Excellent outcomes have been reported, with rare local relapse, after sublobar resection in this setting.
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Surgical Risk Assessment Largely as a result of smoking-related pulmonary dysfunction, a substantial number of patients with localized NSCLC are considered at high risk for surgery. In a national database review of early-stage NSCLC between 2003 and 2007, , 70% of patients were primarily treated with surgery.
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Guidelines from the American College of Chest Physicians detail the physiologic assessment of patients considered for lobectomy. 13 Postoperative predicted forced expiratory volume in the first second of expiration and postoperative predicted diffusing capacity of lung for carbon monoxide are the most common criteria for assessing risk for anatomic resection. 13 If suitability for lobectomy remains unclear after pulmonary function testing, cardiopulmonary exercise testing with maximal oxygen consumption (VO 2 max), stair climbing, or exercise oxygen desaturation testing should be performed to better assess functional status. The impact of surgeon experience also should be considered given the suggestion of improved outcomes with board certified specialized thoracic surgeons compared with surgeons without specialty certification.
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Treatment Options for High-Risk Patients
Although prospective research in high-risk patients was limited before the mid-1990s, competing treatment alternatives have emerged that have resulted in an increased focus on the management of this population. Several prospective trials have now been completed that are specific to high-risk patients.
Limited resection
Considerations for limited resection in candidates for lobectomy are detailed in Treatment Considerations for Fit Patients. One of the first prospective trials for high-risk patients with stage I NSCLC was conducted by the Cancer and Leukemia Group B (CALGB 9335), which used video-assisted thoracoscopic wedge resection with adjuvant radiotherapy to evaluate for pathologic stage I NSCLC. 15 Eligibility criteria were stringent (Table 1) such that the median preoperative forced expiratory volume was 10.88 L and 10% of patients were oxygen dependent before surgery. The very-high-risk nature of the study population may explain the study outcomes because median overall survival was 32 months and , 30% of patients survived 5 years.
A more recent trial from the American College of Surgeons Oncology Group (ACOSOG Z4032) randomly assigned patients to sublobar resection or sublobar resection plus brachytherapy. 16 Eligibility criteria were more liberal than for the CALGB 9335 study (Table 1) , and accordingly, outcomes were better, with a 3-year overall survival of 71% in both arms. Although brachytherapy did not reduce the local tumor recurrence rate as hypothesized, local recurrence was lower than reported in many retrospective trials. Overall local relapse was approximately 12% in both arms, whereas staple-line relapse was , 10%. The difference in overall survival between ACOSOG Z4032 and CALGB 9335 may largely be explained by patient selection characteristics and illustrates the challenge in comparing results across trials in high-risk populations.
Stereotactic body radiotherapy
The concept of stereotactic body radiotherapy (SBRT) for lung cancer was borne in large part from experience with using stereotactic radiosurgery for small brain tumors. The challenge of confidently treating a moving target with intense radiotherapy has been met by advances in imaging, including four-dimensional computed tomography (CT) acquisition for radiotherapy planning, and the introduction of imageguided radiotherapy. Early prospective trials from Indiana University established that very high radiation doses could be delivered in three fractions by using SBRT. 17 Although treatment had acceptable toxicity overall, increased severe complications, including treatment-related death, was observed after treatment of tumors located centrally in proximity to the bronchial tree. The design of a phase II Radiation Therapy Oncology Group study (RTOG 0236) was informed by the Indiana University experience because only peripheral tumors were eligible. 18 A dose of 60 Gy was given in three fractions for tumors as large as 5 cm. Primary control at 93% was reported, with a median follow-up of 4 years with a 40% 5-year survival. No treatment-related deaths occurred, but in addition to expected modest rates of pulmonary toxicity, unexpected chest wall toxicity was reported after treatment of very peripheral lesions, which led to the establishment of rib and chest wall normal tissue constraints in subsequent trials. Select multi-institutional SBRT trials are listed in Table 2 .
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Fractionated radiotherapy Outcomes with SBRT were markedly better than historical reports of fractionated radiotherapy with the added benefit of patient convenience. A recently reported randomized study performed in Sweden compared SBRT (66 Gy in three fractions) with fractionated radiotherapy (70 Gy in 35 fractions). 23 Progression-free or overall survival were not different between treatment arms, although a trend was observed toward increased tumor control and significantly higher health-related quality of life values in the SBRT cohort. Hypofractionated radiotherapy can permit treatment to be completed in approximately one half the time of traditional 
COMPARISONS OF SURGERY AND SBRT IN HIGH-RISK PATIENTS Published Guidelines
Guidelines from the American College of Chest Physicians and Society of Thoracic Surgeons were published in 2013. 27 Although sublobar resection was recommended over nonsurgical therapy for patients who may tolerate an operation but not a lobar resection, prospective comparative data were lacking. A subsequent review suggested that anatomic segmentectomy or wide wedge resection be considered for high-risk patients and that SBRT is preferred for patients treated surgically. 28 National Comprehensive Cancer Network (NCCN) clinical practice guidelines also suggest that SBRT be the preferred option for patients who are not fit for surgery, 29 but considerations of SBRT versus sublobar resection in high-risk patients are not addressed. A large overview of published literature found similar outcomes for SBRT and sublobar resection, although 3-year overall survival was higher with sublobar resection. 30 The difference in overall survival is likely explained in part by a bias to treat healthier patients with resection. Several additional retrospective reports and database analyses have compared SBRT and sublobar resection. 31, 32 Although control for comorbidities was attempted by using matched-pair or propensity analysis, discordant results were reported. Moreover, comparisons of local tumor control is challenged by different definitions used in surgical and SBRT series and by radiographic interpretation after SBRT. Published database comparisons of surgery and SBRT are listed in Table 3 .
33-37
The variation in published data emphasizes the need to successfully complete prospective comparative trials of sublobar resection and SBRT. A recently activated multiinstitutional study in the United States uses a novel design that allows patients to be followed prospectively regardless of whether they accept the assigned treatment. 38 SBRT as an Alternative to Surgery in Standard-Risk Patients Modest-sized phase II trials of SBRT for fit patients have been completed. The Japan Clinical Oncology Group (JCOG 0403) included 64 operable patients and showed absolute local tumor control of 86% and 3-year local progression-free survival of 68.5% after SBRT. 21 A similar RTOG trial reported a 2-year primary tumor failure rate of 7.7% in 26 eligible patients. 39 Data from two randomized phase III studies that compared SBRT and lobectomy for operable stage I NSCLC also have been published. 40 Both trials closed prematurely as a result of poor accrual, and only 57 patients in total were analyzed. Although 3-year overall survival favored SBRT, experience at this point is not sufficient to suggest that a nonsurgical approach be considered outside a clinical trial. SYSTEMIC CHEMOTHERAPY Systemic therapy typically is considered after lobectomy for stage I tumors . 4 cm on the basis of a post hoc analysis of a randomized trial that evaluated adjuvant carboplatin and paclitaxel. 41 The therapeutic benefit of systemic chemotherapy in a medically operable population has not been well studied, although many SBRT reports reflected that larger tumors are associated with higher rates of distant relapse. This population may also have a higher risk of local and nodal relapse. Novel strategies to assess the impact of systemic chemotherapy on patterns of failure in the high-risk population are needed.
CURRENT APPROACH
The optimal management for patients with early-stage lung cancer is best decided through a collaborative multidisciplinary approach that includes thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, and pathologists. Operationally, we approach patients who have not yet had an initial evaluation and diagnosis separately from patients who already have received a pathologic diagnosis. Baseline pulmonary function is obtained for all patients to guide counseling about treatment options. For patients with adequate performance status yet poor measured pulmonary function, VO 2 max is obtained. Typically, a VO 2 max . 10 mL/kg/min indicates sufficient reserve for a sublobar resection, and . 15 mL/kg/min is sufficient for lobectomy. 42 Pulmonary rehabilitation is considered for patients with borderline resectable tumors, and smoking cessation counseling is recommended for all patients. The extent of invasive staging practically depends on patient and tumor factors. Fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is routinely obtained in all patients to assess for regional adenopathy, distant disease, and additional parenchymal lung lesions. For peripheral lesions , 3 cm without mediastinal adenopathy on FDG-PET or CT imaging, further assessment of the mediastinum is not justified. For example, a recent study in 284 patients with clinical stage I disease by PET and CT imaging demonstrated occult mediastinal node involvement in , 7% of patients, and all were centrally located. 43 Occult N2 disease is more common with centrally located and T2 lesions, 43 and the choice of mediastinal node assessment depends on the functional status of the patient; mediastinoscopy either in a separate procedure or at the time of planned lobectomy is more common in surgical patients, whereas endobronchial ultrasound is considered in select high-risk patients. Minimally invasive lobectomy is our standard approach for fit patients with stage I cancers, and enrollment in the lobectomy versus sublobar resection trial is encouraged for lesions , 2 cm. Lymph node assessment at the time of surgery begins with the sampling of three separate mediastinal lymph node stations. For right-side tumors, levels 2R, 4R, 9R, and 7 are sampled, and for left-side tumors, levels 5, 6, 7, and 9L are sampled. The American College of Surgeons Commission on Cancer also recommends the sampling of 10 regional lymph nodes, a standard that has been challenging to meet in practice. Adjuvant chemotherapy may be considered for resected lesions . 4 cm, with consideration of enrollment in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, which involve genetic screening of tumors for specific gene mutations and testing of the relevant targeted agents. 44 High-risk patients are evaluated by a thoracic surgeon and a thoracic radiation oncologist and are offered participation in the clinical trial that compares sublobar resection and SBRT. If patients undergo sublobar resection, we attempt to achieve margins of at least 1 cm, although some experience suggests that the margin should be based on tumor size, with a margin . 1 cm to reduce the risk of relapse. 45 For patients who choose SBRT, a range of dose and fractionation regimens is outlined in NCCN guidelines. 29 Maintaining SBRT radiation dose intensity is important, although even single-fraction regimens may be effective. We generally use a risk-adapted approach taken from the Vrije Universiteit Medical Center and RTOG experience 46 wherein very peripheral lesions near the chest wall are treated with 60 Gy in five fractions and central lesions with 50 to 60 Gy in five fractions, whereas optimally located lesions are treated in three fractions of 54 Gy. Adherence to normal tissue constraints, per NCCN guidelines, 29 during treatment planning and implementation of a meticulous quality assurance program are critical for a safe SBRT program. Not all patients with stage I NSCLC benefit from definitive therapy, but a subset in whom treatment should be withheld is not clearly defined. Analysis of the National Cancer Database showed that patients older than age 70 years had improved survival with SBRT compared with observation, even when accounting for comorbidities, and the benefit held even in patients 85 years and older.
is associated with a decline in untreated elderly patients and improved overall survival.
As such, most patients with medically inoperable tumors are offered noninvasive therapy with SBRT, and the option of RFA also is discussed. A pathologic diagnosis is preferred, although treatment based purely on imaging characteristics is offered to very select patients at high risk for complications with invasive biopsy. Severe chronic obstructive lung disease does not necessarily increase SBRT-related toxicity, although patients with interstitial lung disease may be at high risk for complications. 48 Post-treatment surveillance is important for this patient population given the risk of relapse and the frequency of new primary lung cancers. NCCN guidelines recommend CT imaging every 6 to 12 months for the first 2 years after therapy followed by annual imaging. 29 FDG-PET imaging after SBRT can be difficult to interpret and is not obtained routinely absent a suspicious finding on CT imaging. Experience with recognizing the typical image changes after SBRT is important both for the detection of persistent disease early and for the avoidance of unnecessary additional diagnostic procedures. Although limited published data are available with regard to treatment of locally relapsed disease, salvage treatment with repeat SBRT, RFA, and surgical resection can be considered in select patients.
